Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening.

The colony formation assay (CFA) is the gold standard for measuring the effects of cytotoxic agents on cancer cells in vitro; however, in its traditional 6-well format, it is a time-consuming assay, particularly when evaluating combination therapies. In the interest of increased efficiency, the 6-well CFA was converted to a 96-well format using an automated colony counting algorithm. The 96-well CFA was validated using ionizing radiation therapy on the FaDu (human hypopharyngeal squamous cell) and A549 (human lung) cancer cell lines. Its ability to evaluate combination therapies was investigated by the generation of dose-response curves for the combination of cisplatin and radiation therapy on FaDu and A549 cells. The 96-well CFA was then transferred to a robotic platform for evaluating its potential as a high-throughput screening (HTS) readout. The LOPAC1280 library was screened against FaDu cells, and eight putative hits were identified. Using the 96-well CFA to validate the eight putative chemicals, six of the eight were confirmed, resulting in a positive hit rate of 75%. These data indicate that the 96-well CFA can be adopted as an efficient alternative assay to the 6-well CFA in evaluating single and combination therapies in vitro, providing a possible readout that could be used on a HTS platform.

[1]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[2]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[3]  J. Pignon,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .

[4]  Bert Gunter,et al.  Improved Statistical Methods for Hit Selection in High-Throughput Screening , 2003, Journal of biomolecular screening.

[5]  P. Wylie,et al.  Determination of cell colony formation in a high-content screening assay. , 2007 .

[6]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[7]  T. Puck,et al.  ACTION OF X-RAYS ON MAMMALIAN CELLS , 1957, The Journal of experimental medicine.

[8]  P. Wylie,et al.  Determination of Cell Colony Formation in a High-Content Screening Assay , 2005, Clinics in laboratory medicine.

[9]  R. Himes,et al.  Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. , 1976, Cancer research.

[10]  C. Reynolds,et al.  DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. , 2005, Methods in molecular medicine.

[11]  J. Krieger,et al.  A quantitative chemiluminescent method for studying replicative and stress-induced premature senescence in cell cultures. , 2008, Analytical biochemistry.

[12]  Brian J. Smith,et al.  Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. , 2007, International journal of radiation oncology, biology, physics.

[13]  D. Colomer,et al.  Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B‐chronic lymphocytic leukaemia cells , 1998, British journal of haematology.

[14]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[15]  F. Förster,et al.  Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[17]  G. Jakse,et al.  Hyperfractionated, accelerated radiotherapy and concurrent chemotherapy in locally advanced bladder cancer. , 1987, European urology.

[18]  B. Stockwell.  Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[19]  Christine C. Hudson,et al.  Quantitative Cell-Based High-Content Screening for Vasopressin Receptor Agonists Using Transfluor®Technology , 2005, Journal of biomolecular screening.

[20]  A. Giaccia,et al.  Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. , 1997, Cancer research.

[21]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[22]  G. Steel,et al.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. , 1979, International journal of radiation oncology, biology, physics.

[23]  Robert Nadon,et al.  HTS-Corrector: software for the statistical analysis and correction of experimental high-throughput screening data , 2006, Bioinform..

[24]  R. Maestro,et al.  All‐TRANS, 13‐CIS and 9‐CIS retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: Implications for in vivo retinoic acid use , 1997, International journal of cancer.

[25]  D. Muir,et al.  An enzyme-linked immunosorbent assay for bromodeoxyuridine incorporation using fixed microcultures. , 1990, Analytical biochemistry.

[26]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[27]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[28]  Shadi Dalili,et al.  Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen , 2006, Clinical Cancer Research.

[29]  R. Schnell,et al.  Idarubicin: a brief overview on pharmacology and clinical use. , 1997, International journal of clinical pharmacology and therapeutics.

[30]  Joseph D. Mocanu,et al.  Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent , 2006, Molecular Cancer Therapeutics.